| | Study | Area | Follow-up | Design | n, age
(experimental) | n, age (control) | Main outcomes | Complications |
| | Takacs et al. [11] | Hungary | 4 weeks | Prospective case-control | 38, 65.8 (12.4) ys | 38, 66.9 (11.0) ys | Central corneal thickness,
endothelial cell count | NA | | Kranitz et al. [13] | Hungary | 48 weeks | Prospective, randomized study | 20, 68.2 (10.8) ys | 25, 63.6 (13.7) ys | Refractive outcomes | NA | | Filkorn et al. [12] | Germany | 1 month | Prospective case-control | 77, 65.2 (12.6) ys | 57, 64.4 (12.4) ys | CDVA and refractive | NA | | Abell et al. [7] | Tasmania | 3 weeks | Prospective, consecutive,
single-surgeon case-control | 150,72.8 (10.5) ys | 51, 71.8 (10.8) ys | Corneal endothelial cell loss,
CDVA, intraocular pressure,
and refractive outcomes | NA | Conrad-Hengerer
et al. [5] | Germany | 3 months | Randomized intraindividual
cohort study | 73, 70.9 ys | 73, 70.9 ys | Endothelial cell counts and
corneal thickness | FLACS: EIP in 3 eyes;
macular edema in 2 eyes
CPCS: EIP in 2 eyes,
macular edema in 5 eyes | Mastropasqua
et al. [6] | Italy | 24 weeks | Prospective randomized study | 30, 70.2 (2.9) ys | 30, 70.5 (3.2) ys | UDVA, CDVA, and corneal
endothelial cell counts | NA | Mastropasqua
et al. [14] | Italy | 24 weeks | Prospective randomized
clinical study | 60, 69.3 (3.2) ys | 30, 69.1 (3.9) ys | UDVA, CDVA, refractive outcomes | NA | | Krarup et al. [17] | Denmark | 3 months | Prospective case-control | 47 | 47 | UDVA, CDVA, central corneal
endothelialcell count | NA | Conrad-Hengerer
et al. [15] | Germany | 6 months | Prospective randomized
intraindividual cohort study | 100, 71.6 ys | 100, 71.6 ys | Manifest refraction, corrected
distance visual acuity, and
anterior chamber depth | FLACS: 1 eye developed
macular edema; EIP in 3 eyes;
CPCS: 2 eyes developed
macular edema, 1 eye developed
subclinical macular edema,
EIP in 2 eyes | | Yu et al. [16] | China | 3 months | Prospective study | 25, 62.3 (11.6) ys | 29, 56.5 (16.6) ys | CDVA, refractive outcomes | FLACS: pupil miosis in 1 eye,
mild subconjunctival
hemorrhage in 5 eyes,
EIP in 1 eye;
CPCS: posterior capsular
opacification in 2 eyes |
|
|
